Ali Zare Dehnavi on AI’s Impact on Stroke
Ali Zare Dehnavi, Clinical Innovation Adviosr at March Health, shared on LinkedIn:
”One area of AI deployment I’m particularly interested in is acute neurovascular and critical care, where time to diagnosis and team activation directly affects outcomes.
Recent work from Aidoc and Viz.ai shows what meaningful clinical AI actually looks like in practice.
Aidoc’s FDA-cleared stroke suite enables parallel triage of ischemic stroke (LVO on CTA) and intracranial hemorrhage (NCCT), with published data showing ~35–40% reductions in turnaround time for critical findings and faster escalation to treatment teams.
Viz.ai, deployed within real stroke networks, has demonstrated door-in–door-out reductions from ~200 minutes to ~105 minutes in inter-facility stroke transfers, driven by rapid LVO detection, immediate image access, and real-time team communication.
What’s notable here isn’t the algorithms in isolation, but the compression of imaging-to-decision time and earlier coordination across teams.
In stroke care, those gains translate into earlier anticoagulation, faster thrombectomy pathways, and improved functional outcomes reported in multiple centers.”
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
-
Aug 26, 2026, 13:59David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand
-
Aug 26, 2026, 13:54Giuseppe Biondi Zoccai: Congratulations to the Next Editor-in-Chief of the EHJ
-
Aug 26, 2026, 13:25Omar Adwan: Abnormal Nuclear Morphology of Neutrophil
-
Aug 26, 2026, 13:05Preventing Thrombosis with WTDay26
-
Aug 26, 2026, 10:09Gemma Figtree: How Well Do We Predict Heart Attack Risk in Women?
-
Aug 26, 2026, 10:06Understanding and Managing Fatigue in ITP – ITP Support Association
-
Aug 26, 2026, 10:04Abdul Muqtadir Abbasi: When a High INR Hides a Thrombotic Cancer
-
Aug 26, 2026, 09:42Mohammed Alo: What’s Wrong With the New Blood Pressure Guidelines?